| Abstract: |
Anabolic skeletal agents are changing researchers' approach to osteoporosis treatment. Teriparatide, the first available form of parathyroid hormone (PTH) with the most data in men, has emerged as an effective anabolic treatment. This agent increases bone turnover and bone density. In addition, PTH significantly improves skeletal microarchitecture and other bone qualities that contribute to bone strength. These positive effects on several different aspects of bone can accomplish a central goal of therapy, namely to improve the underlying abnormalities that cause skeletal fragility. Although the data for men are not as complete as those available in women, they are nevertheless similar and suggest a similar profile of efficacy and safety. © 2010 Elsevier Inc. All rights reserved. |
